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Spirometry is essential for the diagnosis and severity staging of chronic obstructive
pulmonary disease (COPD). The 2008 Global Initiative for Chronic Obstructive
Lung Disease (GOLD) guidelines
1 recommended a simple classification of
disease severity into four stages, using forced expiratory volume in one second
(FEV1) of the predicted value, and where all values refer to post-bronchodilator
FEV1. Bronchodilator test (BDT), however, is not always performed in clinical
practice and the staging of COPD severity is frequently based on pre-broncho-
dilator spirometry.
For the past few years, an increasing number of articles on COPD have used the
GOLD guidelines for severity staging. Although there were studies apparently
using the post-BDT spirometry for COPD staging,
2-4 a number of previous studies
have also used pre-bronchodilator values, or did not specify which one was used
when applying the GOLD guidelines.
5-8 While irreversible airflow obstruction is
the hallmark of COPD, many patients with COPD have a reversible component.
9
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Purpose: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines for chronic obstructive
pulmonary disease (COPD) uses the post-bronchodilator spirometry for diagnosis and severity staging. We
evaluated differences in the severity classification of COPD, based on pre- and post-bronchodilator spirometry.
Materials and Methods: From 2000 to 2004, 207 COPD patients who underwent spirometry before and after
inhalation of 400 µg of fenoterol were analyzed. A responder to the bronchodilator test (BDT) was defined by the
American Thoracic Society (ATS) as an increase in forced expiratory volume in one second (FEV1) or forced vital
capacity ≥ 12% and ≥ 200 mL, and by the European Respiratory Society (ERS) as an increase in FEV1 ≥ 10% of
the predicted value. COPD severity was classified according to the 2008 GOLD guidelines. Results: For the entire
study population, the FEV1 increased by 11.8 ± 12.5% of baseline after BDT and 41.1% and 27.1% of subjects
were classified as responders using the ATS and ERS criteria, respectively. Based on pre-BDT spirometry, 55, 85,
58, and 9 patients were classified as Stage I-IV COPD, respectively. Sixty-seven (32.4%) patients changed severity
staging after BDT, including 20.0%, 28.2%, 44.8%, and 66.7% of pre-BDT patients Stages I through IV, respectively.
More ATS or ERS BDT-responders had a change in severity staging than non-responders (52.9% vs. 18.9% and
62.5% vs. 21.2%, both p < 0.001). Conclusion: Our data suggest that the severity staging of COPD using pre-BDT
spirometry might lead to significant differences as compared to staging, based on post-BDT spirometry, as
recommended by the current GOLD guidelines.
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INTRODUCTIONIt must be acknowledged, however, that in COPD patients,
the staging of severity using pre-BDT spirometry tends to
be overestimated due to some limitation of airflow reversi-
bility in COPD. In the absence of such measurements, it
may not be possible to classify subjects into the COPD
severity stages.
10
The purpose of this study was to evaluate the differences
in COPD severity staging by comparing pre- and post-
bronchodilator spirometric data.
Patient selection
From 2000 to 2004, consecutive patients with a physician
diagnosis of COPD and referred to the Lung Function
Laboratory of the National Taiwan University Hospital for
BDT were recruited. The diagnosis of COPD was based
on the medical history, symptoms, chest radiograph and
spirometry. The diagnosis was confirmed by the lung
function criteria of the GOLD guideline.
1 Patients with
other chronic respiratory diseases (occupational lung
disorder, bronchiectasis, interstitial lung disease, tuber-
culosis, or malignancy), previous thoracic surgery, or a
history of asthma were excluded. Patients who had used an
inhaled short-acting bronchodilator within the previous 12
hours or an inhaled/oral long-acting bronchodilator within
the previous 24 hours were likewise excluded.
Measurements
Spirometry was performed with a computerized spiro-
meter (MST-PFT, Germany) by a trained technician accord-
ing to the American Thoracic Society (ATS) criteria.
11 The
tests were performed with the patient seated in an upright
position, and using a nose-clip and breathing through a
non-compressible mouthpiece. After taking baseline mea-
surements, all of the patients inhaled 400 µg of fenoterol
(Boehringer Ingelheim Ltd, Burlington, Ontorio, Canada).
Spirometry was repeated 30 minutes after inhalation of the
bronchodilator.
A positive BDT was based on the criteria set by the
ATS
12 [increase in either FEV1 or forced vital capacity (FVC)
by 12% of baseline, and at least 200 mL] and by the Euro-
pean Respiratory Society
13 (ERS, increase in  FEV1 by
10% of predicted values). Using both the pre- and post-
BDT FEV1 percentage of predicted value
14 when the  FEV1/
FVC ratio was < 70%, the severity of COPD was classified
into: Stage I (mild; ≥ 80%), Stage II (moderate; 50 to
79%); Stage III (severe; 30 to 49%); and Stage IV (very
severe; < 30%) according to 2008 GOLD guidelines.
1 Non-
COPD was noted when the  FEV1/FVC ratio was ≥70%.
Measurements before and after BDT were compared,
including spirometric parameters (FEV1, FVC, and  FEV1/
FVC ratio), with the severity staging of COPD. The correla-
tion between bronchodilator response and pre- or post-
BDT  FEV1 were analyzed. Finally, the differences in
severity staging by pre- and post-BDT spirometry in res-
ponders and non-responders were compared.
Analysis
The clinical variables recorded included age, gender, body
mass index, and smoking status. Data are expressed as
mean ± standard deviation (SD) for continuous variables
or number (percentage) for categorical variables. Cate-
gorical variables were analyzed by the χ 2 test. The paired-
sample t-test was applied to compare pre- and post-BDT
spirometry. In order to investigate the dependence of conti-
nuous variables, linear regression analysis was applied and
the Pearson correlation coefficient was used as a measure
of the extent of the relationship. p values of < 0.05 were
considered statistically significant. All of the statistical
analyses were performed using the statistical software
SPSS Version 10.0 (SPSS Inc, Chicago, IL, USA).
The demographic data of the 207 patients in this study are
shown in Table 1. All of the following data had normal
distribution, as checked by the D’Agostino-Pearson test:
body mass index (p = 0.287), FEV1 percentage of pre-
dicted value (pre-BDT: p = 0.076; post-BDT: p = 0.201),
and FVC percentage of predicted value (pre-BDT: p =
0.312; post-BDT: p = 0.324). The mean changes of  FEV1
and FVC after BDT, expressed by absolute value, percen-
tage of baseline, and percentage of predicted value, were
0.13 ± 0.14 and 0.20 ± 0.25 liter, 11.8 ± 12.5% and 8.9 ±
11.5%, and 6.3 ± 6.3% and 7.2 ± 8.7%, respectively. The
changes in FEV1 during BDT were weakly correlated with
the pre-BDT  FEV1 (r = -0.2, p = 0.004) but not with post-
BDT FEV1 (p = 0.26) values. Of the 207 patients, 85
(41.1%) and 56 (27.1%) were classified as responders by
the ATS and ERS criteria, respectively.
The results of COPD severity staging using pre- and
post-BDT FEV1 are demonstrated in Table 2. Fifty-five
(26.6%), 85 (41.1%), 58 (28.0%), and 9 (4.3%) patients
were classified as Stage I, II, III, and IV, respectively, using
pre-BDT spirometry, and 12 (5.8%), 66 (31.9%), 88
(42.5%), 38 (18.4%), and 3 (1.4%) patients were classified
as non-COPD, and Stage I, II, III, and IV, respectively,
using post-BDT spirometry. The 12 patients classified as
non-COPD after BDT either came from pre-BDT Stages I
or II. As a whole, 67 (32.4%) patients had pre-BDT stages
different from post-BDT stages. In patients with pre-BDT
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MATERIALS AND METHODS
RESULTSStage I to IV, 11 (20.0%), 24 (28.2%), 26 (44.8%), and 6
(66.7%) patients changed their severity staging after BDT
(Fig. 1). The relation between percentage and pre-BDT
stage was statistically significant (p = 0.004). Among the
responders according to both the ATS and ERS criteria,
more patients changed their severity staging after BDT
than the non-responders.
In the present study, we demonstrated a significant dif-
ference in the severity staging of COPD patients by pre-
BDT spirometry instead of post-BDT spirometry. We also
observed that patients with a higher pre-BDT severity
staging were more likely to change their staging based on
post-BDT spirometry. Furthermore, even in the so-called
“non-responders”, changes in severity staging accounted
for a substantial proportion of COPD patients.
In our study population, the mean bronchodilator res-
ponse in  FEV1 was 0.13 liter (11.8% of baseline) while 85
(41.1%) and 56 (27.1%) of all COPD patients were classi-
fied as responders according to the ATS and ERS criteria,
respectively. These data were comparable with previous
reports.
15,16 In the study by Perng and co-workers,
15 48 (55%)
among 88 smoking-related COPD patients were classified
as responders according to the ATS criteria, with a mean
change in  FEV1 of 0.18 liter (14.4%). In another series,
16
the mean bronchodilator response among 123 COPD
patients with a mean  FEV1 of 48.9% was 0.15 liter (10%),
and 58 (47%) and 19 (15%) patients were classified as
responders according to the ATS and ERS criteria, respec-
tively. Therefore, a significant change in staging could not
simply be attributed to a more “asthmatic” COPD popula-
tion in the study.
We observed that the possibilities of changing severity
staging after BDT were associated with pre-BDT stages. It
seemed that the more severe the pre-BDT stage, the higher
the probability of difference. It could be partially explained
by the weak and inverse correlation between pre-BDT  FEV1
and changes in  FEV1 percentage of predicted values after
BDT. This association was also demonstrated by Perng, et
al.,
15 but not by Quadrelli, et al.
17 and Calverley, et al.
18
Another explanation of the stage-related incidence is the
diverse FEV1 intervals of the severity stages. In Stage III
COPD, the narrower FEV1 interval (30% to 49%) resulted
in a higher incidence of staging difference than Stage II
COPD. Furthermore, in Stage IV COPD, the FEV1 actually
ranged from 23% to 29% in our study, leading to the
highest percentage of staging difference.
In our study, 12 of the patients with pre-BDT Stages I-II
had an FEV1/FVC ratio ≥ 70% after BDT (Table 2). Since
Sheng-Hsiang Lin, et al.
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Fig. 1. Percentage of patients changed in severity class after BDT. The relation
between percentage and pre-BDT stage was statistically significant (p= 0.004).
BDT, bronchodilator test.
Table 1.Demographic and Spirometric Characteristics of the
207 Patients with Chronic Obstructive Pulmonary Disease
Male, n (%) 188 (90.8) 
Age, yr 70.2 ± 10.5
Height, cm 161.1 ± 8.0
Weight, kg 56.1 ± 12.8
BMI, kg/m
2 23.2 ± 3.6
Smoking status
Current smoker 106 (51.2)
Ex-smoker 56 (27.1)
Never smoker 45 (21.7)
Responder
ATS criteria, n (%) 85 (41.1) 
ERS criteria, n (%) 56 (27.1) 
Spirometry, pre-bronchodilator
FEV1 / FVC, % 53.0 ± 11.6
FEV1, liter 1.36 ± 0.52
% predicted 64.5 ± 22.8
FVC, liter 2.53 ± 0.66
% predicted 91.5 ± 19.9
Spirometry, post-bronchodilator
FEV1 / FVC, % 54.3 ± 12.0*
FEV1, liter 1.49 ± 0.52*
% predicted 70.8 ± 22.4*
FVC, liter 2.73 ± 0.68*
% predicted 98.7 ± 19.4*
BMI, body mass index; ATS, American Thoracic Society; ERS, European 
Respiratory Society; FEV1, forced expiratory volume in 1 second; FVC, forced
vital capacity. Data are presented as n (%) and mean ±SD. 
*p< 0.01 versus pre-bronchodilator value.COPD, by definition, is never completely reversible, the
question arises on whether or not the diagnosis of COPD is
accurate. In view of the facts that the pre-BDT  FEV1/FVC
ratio (68.1 ± 1.7%) approximated the cut-off value in these
patients and that the increase of  FEV1 in most (75%) did
not exceed the 95% confidence interval after placebo
inhalation,
19 caution should be exercised in interpreting
these results.
Of special interest was a 79-year-old man whose  FEV1
values decreased from 81.5% to 75.3% of predicted value
after BDT, leading to a shift in COPD severity from stage I
to stage II. This might result from a paradoxical response
to inhaled fenoterol with a chlorofluorocarbon metered
dose inhaler (CFC-MDI). In a study involving 679 patients
with chronic airway obstruction, the incidence of paradoxi-
cal reaction (defined as a fall in  FEV1 of > 15% following
inhalations of ipratropium/fenoterol with CFC-MDIs) was
1.2%.
20 In an another study,
21 the incidence of asympto-
matic drop in FEV1 > 15% in 1,538 COPD patients was
1.8%. Another possibility for the decrease in FEV1 is that
bronchoconstriction might be triggered by repeated maxi-
mum respiratory maneuvers during spirometry.
22
In the current GOLD guidelines,
1 patients with FEV1
< 50% of predicted plus the presence of chronic respiratory
failure should be classified as Stage IV COPD, even if the
FEV1 is > 30% of predicted value. In our study population,
only three patients were in GOLD stage IV, and none of
the patients with FEV1 < 50% had chronic respiratory
failure. One of the possible reasons for this is that these
patients usually cannot tolerate the procedure of spirometry.
Another explanation is that results of arterial blood gases
were not available in the majority of our patients.
We observed in this study that more than half of BDT
responders, defined either by the ATS or the ERS criteria,
had a different severity staging after BDT. It was notewor-
thy that changes in staging even among non-responders
were observed in about one-fifth. Since the criteria are
arbitrarily set, the use of pre-BDT spirometry for COPD
severity staging in non-responders is also inappropriate.
Regular treatment with inhaled glucocorticosteroids is
recommended for Stage III and IV COPD patients with
repeated exacerbation to reduce the frequency of exacerba-
tions.
1 In our study, 44.8% of pre-BDT Stage III patients
became Stage II after BDT, suggesting that selection of
pre- or post-BDT FEV1 might have a significant impact on
the indication of ICS in COPD patients which were shown
to be a risk factor for fracture.
23,24
It is well recognized that day-to-day variation of bron-
chodilator response to β2-agonist exists,
25 and that the
maximal attainable FEV1 is the best spirometry index in
survival prediction.
15 The past work has shown that eosino-
philic inflammation may play a substantial role in COPD.
26
Hence, a real ceiling of spirometry by a course of steroid
may be achieved in some COPD patients. However, the
benefits of such measures remain unclear.
In conclusion, the use of pre-BDT spirometry for COPD
severity staging may lead to significantly different results
from those based on post-BDT spirometry. It seems that a
stricter application of the GOLD or the ATS guidelines,
using post-BDT spirometry, should be emphasized, even
in so-called “non-responders”.
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